Not that you would know it from the share price reaction but their is a tonne of incrementally positive news in the 4C.
- First ERT partnered contract for a Phase II with a Major Pharma (probably small but a start to that partnership) - Record Q3 of sales contracts (US$ 13+ million) - Revenue Back Log now US$ 79.7 million a US$ 5 million build in the last 3 months - A strengthening pipeline of Clinical Trials work - Net Cash of @ US$ 18 million (A$ 22 million) with a further US$ 2.4 million (A$ 2.9 million) to add if they get the forgiveness on the paycheck protection program.
Lots to like and that is before you get to Aducanumab approval decision and we should also probably mention the recent positive news around the Biogen/Eisai Lecanemab Clarity AD trial update and of course the Lilly Phase II Donanemab results.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)